aTyr Pharma Shares Continue Downward Spiral Following Clinical Trial Failure
Published on 09/26/2025 at 12:54 | Redaktion boerse-global.de
The stock of biopharmaceutical company aTyr Pharma extended its decline in after-hours trading on Thursday, shedding nearly 6 percent. This persistent sell-off reflects continued investor anxiety in the wake of the failed EFZO-FIT
Phase 3 clinical trial for its drug candidate, efzofitimod, in patients with pulmonary sarcoidosis.
On September 15, the company disclosed that its lead drug candidate had failed to meet the primary endpoint of the crucial study. The market’s reaction was swift and severe, erasing more than 80 percent of the stock’s value in a single day. The official data contained within the subsequent 8-K filing revealed disappointing figures.
According... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
